

## Treatment with Nivolumab

---

Reference Number: F4594  
Date of Response: 16<sup>th</sup> June 2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

### **Request and Royal Devon's Eastern FOI Office Response**

Q1. In the last 3 months, how many patients have been initiated\* on the following agents for treatment for melanoma?

- Nivolumab (monotherapy) - **0**
- Nivolumab AND Ipilimumab (combination) - **0**

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q2. In the last 3 months, how many patients have been initiated\* on the following agents for treatment for Renal Cell Carcinoma?

- Nivolumab + Cabozantinib - **0**
- Avelumab + Axitinib – **0**

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

**In accordance with section 40 (2) of the Freedom of Information Act 2000, We are unable to provide the figures for the following treatments:**

- **Nivolumab (monotherapy)**
- **Nivolumab + Ipilimumab**

**We can confirm that this data is held by the Trust, however, In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide these figures as the number of patients treated using the above is less than five. Releasing this data could risk the identification of these patients. This would breach Caldicott principles and principle One of the GDPR.**

**This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.**

Q3. In the past 3 months, how many patients have been initiated\* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:

- Nivolumab (monotherapy) - 0
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) – 0

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.